Posted by Michael Wonder on 13 Oct 2021
FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
13 October 2021 - Today, the FDA approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥1), as determined by an FDA approved test.
FDA also granted regular approval to pembrolizumab as a single agent for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumours express PD-L1 (CPS ≥1) as determined by an FDA-approved test. In June 2018, FDA had granted accelerated approval to this indication with the companion diagnostic, PD-L1 IHC 22C3 pharmDx (Dako North America).
